Novartis Scemblix Phase III Data Shows Superior Efficacy With A Favorable Safety And Tolerability Profile Vs. Standard-Of-Care TKIs In Adults With Newly Diagnosed CML
Portfolio Pulse from Benzinga Newsdesk
Novartis' Scemblix (asciminib) has shown superior efficacy and a favorable safety profile compared to standard-of-care TKIs in a Phase III trial for newly diagnosed CML patients. The trial met both primary endpoints, demonstrating higher MMR rates and fewer adverse events. Scemblix has been granted US FDA Breakthrough Therapy Designation and is under review.
May 31, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis' Scemblix has demonstrated superior efficacy and safety in a Phase III trial for newly diagnosed CML patients, meeting both primary endpoints. The drug has been granted US FDA Breakthrough Therapy Designation and is under review.
The positive Phase III trial results and FDA Breakthrough Therapy Designation for Scemblix are likely to boost investor confidence in Novartis. The superior efficacy and safety profile compared to standard-of-care TKIs could lead to increased adoption and sales, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100